The Greater Oklahoma City Chamber’s annual State of Health event is about a week away, but that does not mean you won’t be able to attend this informative, worthwhile event. Tickets are still available.
Oklahoma City has steadily – and intentionally – transformed itself into an emerging bioscience and biotechnology player over the last few decades, garnering attention from across the nation and globe.
Editor's note 5-10-22: Stephanie Wierwille, SVP, Integrated Marketing at Revive, is now set to keynote State of Health and will be presenting "Joe Public 2030: Five Potent Predictions Reshaping How Consumers Engage Healthcare."
The National Institutes of Health has selected the Oklahoma Medical Research Foundation to lead a nationwide public-private partnership aimed at developing more effective treatments for autoimmune diseases.
In the rearview are days when Oklahoma City’s key sectors – academia, aerospace, bioscience, energy, healthcare, manufacturing and research – worked solely in silos, and on the road ahead lie opportunities for those industries to cross, merge and collaborate, giving the city a future at becoming a stable, international competitor in the ever-changing global economy.
The highest dose of the investigational drug iberdomide showed a reduction of lupus symptoms by the end of a 24-week, Phase 2 study. OMRF physician-scientist Joan Merrill, M.D., was the lead author of the paper.
VeloCity staff recently visited with OMRF’s new president Dr. Andrew Weyrich to learn more about him, both professionally and personally, and to hear his thoughts about OMRF and his new role there.
After a two-year break due to the pandemic, the Chamber will resume its annual DC Fly-in this year on April 27-28, to provide Chamber members with an opportunity to interact one-on-one with members of Oklahoma’s congressional delegation and defense leaders.
